Results 1 to 10 of about 6,645 (195)

Prurigo Nodularis at Ultra-High-Frequency Ultrasound. [PDF]

Diagnostics (Basel)
Here, we describe the case of a 48-year-old female patient with prurigo nodularis, where B-mode and color-Doppler ultrasound of one nodule was performed; this revealed hypoechoic dermal and hyperechoic epidermal thickening with lesion hypervascularity ...
Michelucci A, Tagliati C, Manzo Margiotta F, Salvia G, Fogante M, Rizzetto G, Corvino A, Molinelli E, Offidani A, Simonetti O, Romanelli M, Dini V.   +11 more
europepmc   +4 more sources

Successful Treatment of Pediatric Atopic Prurigo Nodularis with Dupilumab. [PDF]

Clin Cosmet Investig Dermatol
Purpose This study aims to evaluate the efficacy and safety of Dupilumab in treating pediatric atopic prurigo nodularis (PN). Patient and Methods We present a case of an 11-year-old child with refractory prurigo nodularis for 9 months, accompanied by ...
Zhang Y, Liang L, Li C.
europepmc   +4 more sources

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report. [PDF]

Clin Case Rep
Recent advancements in understanding the potential pathogenesis of prurigo nodularis (PN) have paved the way for the development of new, targeted therapies.
Mozafari N.
europepmc   +3 more sources

Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature. [PDF]

Dermatol Ther (Heidelb)
Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis characterized by hyperkeratotic nodules and a persistent itch–scratch cycle.
Licata G, Arisi M, Giorgio CM, Ariasi C, Tomasi C, Soglia S, Mezzana S, Galli B, Artelli GL, Rossi M, Catapano C.   +10 more
europepmc   +3 more sources

Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients. [PDF]

Postepy Dermatol Alergol
Introduction Prurigo nodularis (PN) is a chronic pruritic and inflammatory skin disorder and dupilumab is currently the only biologic agent approved in China for the treatment.
Zhao Y, Gao C, Leng H.
europepmc   +2 more sources

Dupilumab-Induced Psoriasis in a Patient With Prurigo Nodularis: A Case Report [PDF]

Cureus
Dupilumab is a monoclonal antibody targeting the interleukin-4 (IL-4) and interleukin-13 (IL-13) receptor complex and is used for the treatment of atopic dermatitis (AD), severe asthma, chronic rhinosinusitis with nasal polyps, and prurigo nodularis (PN).
Ogawa H, Izumi K.
europepmc   +2 more sources

Epidemiology and Severity of Prurigo Nodularis in Europe: A Literature Review with an Application to Italian Data. [PDF]

Dermatol Pract Concept
Introduction Prurigo nodularis is a chronic inflammatory skin disease with recent definition and relatively low prevalence. Information on prurigo nodularis, including its epidemiology, severity, and burden of disease, is still scanty.
Patruno C, Pelucchi C, Galeone C, Emmi M, Amerio P.   +4 more
europepmc   +2 more sources

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.

JAMA Dermatol
Importance Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe pruritus and nodule formation, significantly affecting patients' quality of life. There is an unmet need for effective therapies to address both symptoms and
Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF.   +6 more
europepmc   +2 more sources

Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups. [PDF]

J Eur Acad Dermatol Venereol
Prurigo nodularis (PN) is a severe, intensely pruritic subtype of chronic prurigo for which the molecular basis and interplay between pathophysiologic mechanisms and clinical manifestations are poorly understood.
Ständer S, Guttman-Yassky E, Yosipovitch G, Wiegmann H, Metze D, Kim M, Del Duca E, Bondensgaard K, Paolini JF, LOTUS‐PN Investigators Group.   +9 more
europepmc   +2 more sources

Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims Database. [PDF]

J Clin Med
Background/Objectives: Prurigo nodularis (PN) is associated with considerable disease burden. Limited information exists about the epidemiology, treatment patterns, and impact of PN.
Igarashi A, Yoshida T, Sunaga Y, Nawata H, Arima K.   +4 more
europepmc   +2 more sources